TEHRAN (FNA) - SpikoGen, a coronavirus vaccine developed by Iranian and Australian researchers, has successfully passed the second trial phase in Iran and started the third phase with participation of 17,000 people.
“In Iran, Cinna Gene Company is participating in the process of producing this vaccine, and the second phase of the clinical trial of the vaccine started and ended in the last two months and received the approval of the Ethics Committee of the Health Ministry,” Payam Tabarsi, one of the main Iranian researchers participating in the project, said.
He added that the third phase of the clinical trial of the vaccine will start on Saturday, and noted, “17,000 people will participate in this phase and the third phase of the clinical trial will end within the next one or two months.”
Tabarsi said that the second phase of the clinical trial of the vaccine showed that SpikoGen creates 70% immunity in the body of receivers.
The first phase of the clinical trial was performed on volunteer Australians.
SpikoGen is a recombinant protein subunit vaccine.
Tabarsi had said in July that the SpikoGen vaccine works on a double-dose immunity platform, adding, “The production capacity of this vaccine stands at 5 million doses per month, and fortunately the infrastructures have been prepared and mass production will start necessary licenses are issued.”